Oklo acquired Atomic Alchemy on February 28, 2025 for a total purchase price of $28.4 million ($900K cash plus 820,840 shares of Oklo common stock at $33.39 per share). Atomic Alchemy is pioneering a US-based radioisotope supply chain using its Versatile Isotope Production Reactor (VIPR) technology. The acquisition provides Oklo with diversification into the radioisotope market — estimated at $55.7 billion by 2026 — across healthcare diagnostics, cancer treatment, industrial applications, space, and defence. Long-term synergies exist because Oklo's fast reactors naturally produce radioisotopes as byproducts, and Atomic Alchemy can capture and sell these. Atomic Alchemy intends to be a low-cost US radioisotope producer beginning production in 2026.